ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

Jianfeng Shen, Yang Peng, Leizhen Wei, Wei Zhang, Lin Yang, Li Lan, Prabodh Kapoor, Zhenlin Ju, Qianxing Mo, Ie Ming Shih, Ivan P. Uray, Xiangwei Wu, Powel H. Brown, Xuetong Shen, Gordon Mills, Guang Peng

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

UNLABELLED: ARID1A, SWI/SNF chromatin remodeling complex subunit, is a recently identified tumor suppressor that is mutated in a broad spectrum of human cancers. Thus, it is of fundamental clinical importance to understand its molecular functions and determine whether ARID1A deficiency can be exploited therapeutically. In this article, we report a key function of ARID1A in regulating the DNA damage checkpoint. ARID1A is recruited to DNA double-strand breaks (DSB) via its interaction with the upstream DNA damage checkpoint kinase ATR. At the molecular level, ARID1A facilitates efficient processing of DSB to single-strand ends and sustains DNA damage signaling. Importantly, ARID1A deficiency sensitizes cancer cells to PARP inhibitors in vitro and in vivo, providing a potential therapeutic strategy for patients with ARID1A-mutant tumors.

SIGNIFICANCE: ARID1A has been identified as one of the most frequently mutated genes across human cancers. Our data suggest that clinical utility of PARP inhibitors might be extended beyond patients with BRCA mutations to a larger group of patients with ARID1A-mutant tumors, which may exhibit therapeutic vulnerability to PARP inhibitors.

Original languageEnglish (US)
Pages (from-to)752-767
Number of pages16
JournalCancer Discovery
Volume5
Issue number7
DOIs
StatePublished - Jul 1 2015
Externally publishedYes

Fingerprint

DNA Damage
Neoplasms
Chromatin Assembly and Disassembly
Double-Stranded DNA Breaks
Poly(ADP-ribose) Polymerase Inhibitors
Phosphotransferases
Mutation
Therapeutics
Genes

ASJC Scopus subject areas

  • Oncology

Cite this

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. / Shen, Jianfeng; Peng, Yang; Wei, Leizhen; Zhang, Wei; Yang, Lin; Lan, Li; Kapoor, Prabodh; Ju, Zhenlin; Mo, Qianxing; Shih, Ie Ming; Uray, Ivan P.; Wu, Xiangwei; Brown, Powel H.; Shen, Xuetong; Mills, Gordon; Peng, Guang.

In: Cancer Discovery, Vol. 5, No. 7, 01.07.2015, p. 752-767.

Research output: Contribution to journalArticle

Shen, J, Peng, Y, Wei, L, Zhang, W, Yang, L, Lan, L, Kapoor, P, Ju, Z, Mo, Q, Shih, IM, Uray, IP, Wu, X, Brown, PH, Shen, X, Mills, G & Peng, G 2015, 'ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors', Cancer Discovery, vol. 5, no. 7, pp. 752-767. https://doi.org/10.1158/2159-8290.CD-14-0849
Shen, Jianfeng ; Peng, Yang ; Wei, Leizhen ; Zhang, Wei ; Yang, Lin ; Lan, Li ; Kapoor, Prabodh ; Ju, Zhenlin ; Mo, Qianxing ; Shih, Ie Ming ; Uray, Ivan P. ; Wu, Xiangwei ; Brown, Powel H. ; Shen, Xuetong ; Mills, Gordon ; Peng, Guang. / ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. In: Cancer Discovery. 2015 ; Vol. 5, No. 7. pp. 752-767.
@article{8507f82557f348fe9353f7edba239951,
title = "ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors",
abstract = "UNLABELLED: ARID1A, SWI/SNF chromatin remodeling complex subunit, is a recently identified tumor suppressor that is mutated in a broad spectrum of human cancers. Thus, it is of fundamental clinical importance to understand its molecular functions and determine whether ARID1A deficiency can be exploited therapeutically. In this article, we report a key function of ARID1A in regulating the DNA damage checkpoint. ARID1A is recruited to DNA double-strand breaks (DSB) via its interaction with the upstream DNA damage checkpoint kinase ATR. At the molecular level, ARID1A facilitates efficient processing of DSB to single-strand ends and sustains DNA damage signaling. Importantly, ARID1A deficiency sensitizes cancer cells to PARP inhibitors in vitro and in vivo, providing a potential therapeutic strategy for patients with ARID1A-mutant tumors.SIGNIFICANCE: ARID1A has been identified as one of the most frequently mutated genes across human cancers. Our data suggest that clinical utility of PARP inhibitors might be extended beyond patients with BRCA mutations to a larger group of patients with ARID1A-mutant tumors, which may exhibit therapeutic vulnerability to PARP inhibitors.",
author = "Jianfeng Shen and Yang Peng and Leizhen Wei and Wei Zhang and Lin Yang and Li Lan and Prabodh Kapoor and Zhenlin Ju and Qianxing Mo and Shih, {Ie Ming} and Uray, {Ivan P.} and Xiangwei Wu and Brown, {Powel H.} and Xuetong Shen and Gordon Mills and Guang Peng",
year = "2015",
month = "7",
day = "1",
doi = "10.1158/2159-8290.CD-14-0849",
language = "English (US)",
volume = "5",
pages = "752--767",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

AU - Shen, Jianfeng

AU - Peng, Yang

AU - Wei, Leizhen

AU - Zhang, Wei

AU - Yang, Lin

AU - Lan, Li

AU - Kapoor, Prabodh

AU - Ju, Zhenlin

AU - Mo, Qianxing

AU - Shih, Ie Ming

AU - Uray, Ivan P.

AU - Wu, Xiangwei

AU - Brown, Powel H.

AU - Shen, Xuetong

AU - Mills, Gordon

AU - Peng, Guang

PY - 2015/7/1

Y1 - 2015/7/1

N2 - UNLABELLED: ARID1A, SWI/SNF chromatin remodeling complex subunit, is a recently identified tumor suppressor that is mutated in a broad spectrum of human cancers. Thus, it is of fundamental clinical importance to understand its molecular functions and determine whether ARID1A deficiency can be exploited therapeutically. In this article, we report a key function of ARID1A in regulating the DNA damage checkpoint. ARID1A is recruited to DNA double-strand breaks (DSB) via its interaction with the upstream DNA damage checkpoint kinase ATR. At the molecular level, ARID1A facilitates efficient processing of DSB to single-strand ends and sustains DNA damage signaling. Importantly, ARID1A deficiency sensitizes cancer cells to PARP inhibitors in vitro and in vivo, providing a potential therapeutic strategy for patients with ARID1A-mutant tumors.SIGNIFICANCE: ARID1A has been identified as one of the most frequently mutated genes across human cancers. Our data suggest that clinical utility of PARP inhibitors might be extended beyond patients with BRCA mutations to a larger group of patients with ARID1A-mutant tumors, which may exhibit therapeutic vulnerability to PARP inhibitors.

AB - UNLABELLED: ARID1A, SWI/SNF chromatin remodeling complex subunit, is a recently identified tumor suppressor that is mutated in a broad spectrum of human cancers. Thus, it is of fundamental clinical importance to understand its molecular functions and determine whether ARID1A deficiency can be exploited therapeutically. In this article, we report a key function of ARID1A in regulating the DNA damage checkpoint. ARID1A is recruited to DNA double-strand breaks (DSB) via its interaction with the upstream DNA damage checkpoint kinase ATR. At the molecular level, ARID1A facilitates efficient processing of DSB to single-strand ends and sustains DNA damage signaling. Importantly, ARID1A deficiency sensitizes cancer cells to PARP inhibitors in vitro and in vivo, providing a potential therapeutic strategy for patients with ARID1A-mutant tumors.SIGNIFICANCE: ARID1A has been identified as one of the most frequently mutated genes across human cancers. Our data suggest that clinical utility of PARP inhibitors might be extended beyond patients with BRCA mutations to a larger group of patients with ARID1A-mutant tumors, which may exhibit therapeutic vulnerability to PARP inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85018228755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018228755&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-14-0849

DO - 10.1158/2159-8290.CD-14-0849

M3 - Article

C2 - 26069190

AN - SCOPUS:85018228755

VL - 5

SP - 752

EP - 767

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 7

ER -